Shuiying Hu - Concepedia

Author

Shuiying Hu

St. Jude Children's Research Hospital ORCID

Also Known As

S Hu, S. Y. Hu, Shuiying Hu

341

Publications

4.8K

Citations

H-Index

Concepts

All Affiliations

St. Jude Children's Research Hospital The Ohio State University Johns Hopkins University Erasmus MC Cancer Institute Johns Hopkins Medicine

About

Shuiying Hu is an author at St. Jude Children's Research Hospital specializing in medicine, pharmacology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	925
2	Natural Sciences	4	4	202
3	Engineering	1	1	28
4	Health Sciences	1	1	30
5	Social Sciences	1	1	13

Shuiying Hu

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer Peng Hou, Dingxie Liu, Shan Yuan, Clinical Cancer Research	2007	411
Interaction of Imatinib with Human Organic Ion Carriers Shuiying Hu, Ryan M. Franke, Kelly K. Filipski, Clinical Cancer Research	2008	228
Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer Shuiying Hu, Dingxie Liu, Ralph P. Tufano, International Journal of Cancer Aberrant MethylationBraf MutationOncogenic AgentEpigenetic ChangeGenetics	2006	196
Suppression of BRAF/MEK/MAP Kinase Pathway Restores Expression of Iodide-Metabolizing Genes in Thyroid Cells Expressing the V600E BRAF Mutant Dingxie Liu, Shuiying Hu, Peng Hou, Clinical Cancer Research	2007	194
Uncommon Mutation, but Common Amplifications, of the<i>PIK3CA</i>Gene in Thyroid Tumors Guojun Wu, Elizabeth Mambo, Zhongmin Guo, The Journal of Clinical Endocrinology & Metabolism	2005	189
Crenolanib is active against models of drug-resistant FLT3-ITD−positive acute myeloid leukemia Eric I. Zimmerman, David C. Turner, Jassada Buaboonnam, Blood	2013	182
Pharmacogenetic Pathway Analysis of Docetaxel Elimination Jaap Verweij, G. Cusatis, RH van Schaik, Clinical Pharmacology & Therapeutics	2008	169
Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide Eric I. Zimmerman, Shuiying Hu, Justin L. Roberts, Clinical Cancer Research	2013	157
Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters Shuiying Hu, Zhaoyuan Chen, Ryan M. Franke, Clinical Cancer Research	2009	157
Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy Sijin Guo, Mario Vieweger, Kaiming Zhang, Nature Communications	2020	157

Page 1